Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program

Novartis

Status: Completed

Conditions: Age-related Macular Degeneration (AMD)

Treatments: Other: All participants

Study type: Observational

Funder types: Industry

Identifiers

NCT05066685

CRTH258AUS18

Details and patient eligibility

About

The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program. Evidence was generated to describe their baseline demographic and clinical characteristics.

Full description

The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program.

PSS data was obtained from patients with wet AMD who enrolled in the program for the index period 10/10/2019 to 04/30/2020.

• Identification period of the index period: 10/10/2019 to 04/30/2020
• Index date: Date of enrollment in the PSS program
• Study Period: 10/10/2019 to 04/30/2020

Enrollment: 18,457 patients

Sex: All

Ages: 19 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients were enrolled in the brolucizumab PSS program
• ≥19 years old

Exclusion criteria

• None

Trial design

18,457 participants in 1 patient group

All Participants

Description:

All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program

Treatment:

Other: All participants